Cure My Disease

Don't miss your cure!

 Log in / Sign up

Doctors’ views on fatty liver: a survey reveals gaps in fibrosis testing

NCT ID NCT07682363

Recruiting now Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study surveys physicians in China to understand how they diagnose and manage metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. It focuses on whether and how doctors assess liver fibrosis, a key indicator of disease severity. The goal is to identify barriers to proper evaluation and improve care for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
This study could reveal gaps in how liver fibrosis is assessed in MASLD patients, guiding better training and care standards.
What could go wrong
As a survey, it captures opinions and self-reported practices, not patient outcomes. Results may not reflect actual clinical behavior or apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Novo Nordisk Investigational site

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.